-
公开(公告)号：US5846534A
公开(公告)日：1998-12-08
申请号：US235705
申请日：1994-04-29
IPC分类号： A61K38/00 , C07K16/28 , C07K16/46 , A61K39/395 , C07K16/30
CPC分类号： C07K16/465 , C07K16/2893 , A61K38/00 , C07K2317/24 , C07K2317/734 , C07K2319/00 , C07K2319/02
摘要： An antibody is produced, which will bind effectively with the antigen Campath-1, and which has at least one complementarity determining region of rat origin, as identified in FIG. 2, which may be combined with a range of different foreign variable domain framework regions as desired, including framework regions of human origin.
摘要翻译： 产生抗体，其与抗原Campath-1有效结合，并且其具有至少一个大鼠来源的互补决定区，如图1所示。 2，其可以与期望的一系列不同的外部可变结构域框架区域结合，包括人源的框架区域。
-
22.发明授权Non-depleting CD4-specific monoclonal antibodies for the treatment of insulin-dependent diabetes mellitus (IDDM) 失效用于治疗胰岛素依赖性糖尿病（IDDM）的非消耗性CD4-特异性单克隆抗体
公开(公告)号：US5670150A
公开(公告)日：1997-09-23
申请号：US436843
申请日：1995-05-08
申请人： Anne Cooke , Herman Waldmann
发明人： Anne Cooke , Herman Waldmann
IPC分类号： A61K39/395 , A61K38/00 , A61P3/08 , A61P3/10 , C07K16/28 , C07K16/18 , C07K16/24 , C07K16/26
CPC分类号： C07K16/2812 , A61K38/00
摘要： Non-depleting CD4 monoclonal antibodies may be used in the treatment of insulin-dependent diabetes mellitus.
摘要翻译： 非消耗性CD4单克隆抗体可用于治疗胰岛素依赖性糖尿病。
-
公开(公告)号：USRE43898E1
公开(公告)日：2013-01-01
申请号：US11493016
申请日：1991-09-16
IPC分类号： A61K39/395 , C07K16/18
CPC分类号： C07K16/2812 , A61K38/00 , C07K2317/24 , C07K2319/00
摘要： An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.
摘要翻译： 产生改变的抗体链，其中链的可变结构域的CDR衍生自第一哺乳动物物种。 编码第一种可变结构域的DNA的框架编码区被突变，使得突变的框架编码区编码来自第二种不同哺乳动物物种的框架。 抗体链的每个恒定结构域（如果存在）也衍生自第二哺乳动物物种。
-
公开(公告)号：US08232100B2
公开(公告)日：2012-07-31
申请号：US12841064
申请日：2010-07-21
CPC分类号： C12N5/0639 , A61K2039/5154 , A61K2039/5156 , C12N5/0603 , C12N5/064 , C12N2501/052 , C12N2501/22 , C12N2501/23 , C12N2503/02 , C12N2506/02 , C12N2510/00
摘要： Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
摘要翻译： 公开了胚胎干细胞衍生的树突状细胞，能够成熟的遗传修饰的未成熟树突状细胞，以及用于产生这种细胞的方法。 在一个实施方案中，制备的细胞通过包括以下步骤的方法产生：提供一群胚胎干细胞; 在细胞因子或细胞因子的组合存在下培养胚胎干细胞，其导致胚胎干细胞分化成树突状细胞; 并从培养物中回收树突状细胞。 在另一个实施方案中，细胞可以被遗传修饰。
-
公开(公告)号：US20070092516A1
公开(公告)日：2007-04-26
申请号：US11581008
申请日：2006-10-16
申请人： Herman Waldmann , Mark Frewin
发明人： Herman Waldmann , Mark Frewin
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C12N5/06 , C07K16/30
CPC分类号： C07K16/2809 , A61K38/00 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2319/00
摘要： An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.
摘要翻译： 提供具有对CD3抗原复合物的结合亲和力的IgG抗体，其中在重链中具有可选区域框架以及选自SEQ ID No 2,4和6的氨基酸序列的至少一个CDR，并且各自保守修饰 其轻链具有可变区框架以及选自SEQ ID No 8,10和12的氨基酸序列的至少一个CDR及其各自的保守修饰变体，其特征在于重链可变区框架依次对应 涉及人类序列，轻链可变区框架包括啮齿动物型序列特征的一种或多种特定氨基酸。 新型抗体能够以增强的产量被哺乳动物细胞表达系统表达。
-
26.发明授权公开(公告)号：US07098006B1
公开(公告)日：2006-08-29
申请号：US08459655
申请日：1995-06-02
IPC分类号： C12N15/00
CPC分类号： C07K16/2812 , A61K38/00 , C07K2317/24 , C07K2319/00
摘要： An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species. An antibody which is capable of binding to human CD4 antigen is also provided together with a pharmaceutical composition comprising the antibody.
摘要翻译： 产生改变的抗体链，其中链的可变结构域的CDR衍生自第一哺乳动物物种。 编码第一种可变结构域的DNA的框架编码区被突变，使得突变的框架编码区编码来自第二种不同哺乳动物物种的框架。 抗体链的每个恒定结构域（如果存在）也衍生自第二哺乳动物物种。 能够与人CD4抗原结合的抗体也与包含抗体的药物组合物一起提供。
-
公开(公告)号：US20050118172A1
公开(公告)日：2005-06-02
申请号：US10938874
申请日：2004-09-13
申请人： Geoffrey Hale , Herman Waldmann
发明人： Geoffrey Hale , Herman Waldmann
IPC分类号： A61K39/395 , A61K31/57 , A61K38/00 , A61P37/00 , A61P37/06 , C07K16/28 , A61K31/573
CPC分类号： A61K31/57 , A61K38/00 , C07K16/2893
摘要： The invention relates to the use of an antibody recognising the CDw52 antigen in the treatment of multiple sclerosis. Preferably the antibody is the humanised antibody in the humanised antibody CAMPATH-1H.
摘要翻译： 本发明涉及识别CDw52抗原的抗体在治疗多发性硬化中的用途。 优选地，抗体是人源化抗体CAMPATH-1H中的人源化抗体。
-
公开(公告)号：US06706265B1
公开(公告)日：2004-03-16
申请号：US08478684
申请日：1995-06-07
IPC分类号： A61K39395
CPC分类号： C07K16/2809 , A61K2039/505 , C07K16/00 , C07K2317/24 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/74
摘要： Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.
-
29.发明授权
公开(公告)号：US6056956A
公开(公告)日：2000-05-02
申请号：US470421
申请日：1995-06-06
CPC分类号： C07K16/2815 , C07K16/2812 , A61K2039/505 , A61K38/00
摘要： Tolerance to an antigen is induced in a subject by administering a non-depleting CD4 monoclonal antibody and a non-depleting CD8 monoclonal antibody. Tolerance to the antigen can be induced under cover of these antibodies. A depleting CD4 monoclonal antibody and/or a depleting CD8 monoclonal antibody may be administered prior to the non-depleting antibodies.
摘要翻译： 通过施用非消耗性CD4单克隆抗体和非消耗性CD8单克隆抗体，在受试者中诱导对抗原的耐受性。 可以在这些抗体的覆盖下诱导对抗原的耐受性。 可以在非消耗性抗体之前施用耗尽的CD4单克隆抗体和/或消耗性CD8单克隆抗体。
-
公开(公告)号：US5690933A
公开(公告)日：1997-11-25
申请号：US289532
申请日：1994-08-12
CPC分类号： C07K16/2815 , C07K16/2812 , A61K2039/505 , A61K38/00
摘要： Tolerance to an antigen is induced in a subject by administering a non-depleting CD4 monoclonal antibody and a non-depleting CD8 monoclonal antibody. Tolerance to the antigen can be induced under cover of these antibodies. A depleting CD4 monoclonal antibody and/or a depicting CD8 monoclonal antibody may be administered prior to the non-depleting antibodies.
摘要翻译： 通过施用非消耗性CD4单克隆抗体和非消耗性CD8单克隆抗体，在受试者中诱导对抗原的耐受性。 可以在这些抗体的覆盖下诱导对抗原的耐受性。 可以在非消耗性抗体之前施用耗尽的CD4单克隆抗体和/或描绘CD8单克隆抗体。
-
-
-
-
-
-
-
-
-
搜索结果
44 条记录 (耗时 0.033 秒)
